Veligrotug
- Generic Name
- Veligrotug
Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT01233895
- Locations
- 🇫🇷
Sanofi-Aventis Investigational Site Number 250002, Lille, France
🇫🇷Sanofi-Aventis Investigational Site Number 250003, Vandoeuvre Les Nancy, France
🇮🇹Sanofi-Aventis Investigational Site Number 380001, Torino, Italy
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT00791544
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2011-03-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00774878
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath